TVAX Biomedical, a biotech company focused on cancer cell vacination and T-cell cancer treatment, filed on Monday with the SEC to raise up to $40 million in an initial public offering. The Lenexa, KS-based company, which was founded in 2004 and is currently unprofitable, plans to list on the NASDAQ under the symbol TVAX. Roth Capital is the lead underwriter on the deal. Terms and timing are to be announced.
